Prescient Therapeutics: Progresses trial for novel cancer drug
- Cancer drug developer Prescient Therapeutics (PTX) will proceed to the next trial phase of its novel therapy PTX-100
- The drug is being developed to inhibit the Ras pathway, which helps cancer cells survive and increase
- The drug has so far proved safe and non-toxic to the three enrolled patients, with one patient reporting relief of symptoms
- The trial also will now expand to 24 patients and include solid tumour cancers on top of the blood cancer patients already enrolled
- Final results are a fair way off, but the first-in-class drug could be a game changer in the treatment of advanced cancers
- Prescient Therapeutics is up 8.57 per cent with shares trading for 3.8 cents each
